Drug name - Abraxane

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8314156 ABRAXIS BIOSCIENCE Compositions and methods of delivery of pharmacological agents Dec, 2023

(1 year, 2 months from now)

US7923536 ABRAXIS BIOSCIENCE Compositions and methods of delivery of pharmacological agents Dec, 2023

(1 year, 2 months from now)

US8138229 ABRAXIS BIOSCIENCE Compositions and methods of delivery of pharmacological agents Dec, 2023

(1 year, 2 months from now)

US7923536

(Pediatric)

ABRAXIS BIOSCIENCE Compositions and methods of delivery of pharmacological agents Jun, 2024

(1 year, 8 months from now)

US8314156

(Pediatric)

ABRAXIS BIOSCIENCE Compositions and methods of delivery of pharmacological agents Jun, 2024

(1 year, 8 months from now)

US8138229

(Pediatric)

ABRAXIS BIOSCIENCE Compositions and methods of delivery of pharmacological agents Jun, 2024

(1 year, 8 months from now)

US7820788 ABRAXIS BIOSCIENCE Compositions and methods of delivery of pharmacological agents Oct, 2024

(2 years from now)

US7820788

(Pediatric)

ABRAXIS BIOSCIENCE Compositions and methods of delivery of pharmacological agents Apr, 2025

(2 years from now)

US8268348 ABRAXIS BIOSCIENCE Combinations and modes of administration of therapeutic agents and combination therapy Feb, 2026

(3 years from now)

US9101543 ABRAXIS BIOSCIENCE Combinations and modes of administration of therapeutic agents and combination therapy Feb, 2026

(3 years from now)

US7758891 ABRAXIS BIOSCIENCE Combinations and modes of administration of therapeutic agents and combination therapy Feb, 2026

(3 years from now)

US8034375 ABRAXIS BIOSCIENCE Combinations and modes of administration of therapeutic agents and combination therapy Aug, 2026

(3 years from now)

US9101543

(Pediatric)

ABRAXIS BIOSCIENCE Combinations and modes of administration of therapeutic agents and combination therapy Aug, 2026

(3 years from now)

US8268348

(Pediatric)

ABRAXIS BIOSCIENCE Combinations and modes of administration of therapeutic agents and combination therapy Aug, 2026

(3 years from now)

US7758891

(Pediatric)

ABRAXIS BIOSCIENCE Combinations and modes of administration of therapeutic agents and combination therapy Aug, 2026

(3 years from now)

US8034375

(Pediatric)

ABRAXIS BIOSCIENCE Combinations and modes of administration of therapeutic agents and combination therapy Feb, 2027

(4 years from now)

US9393318 ABRAXIS BIOSCIENCE Methods of treating cancer Mar, 2032

(9 years from now)

US9597409 ABRAXIS BIOSCIENCE Methods of treating cancer Mar, 2032

(9 years from now)

US9393318

(Pediatric)

ABRAXIS BIOSCIENCE Methods of treating cancer Sep, 2032

(9 years from now)

US9597409

(Pediatric)

ABRAXIS BIOSCIENCE Methods of treating cancer Sep, 2032

(9 years from now)

US9511046 ABRAXIS BIOSCIENCE Methods of treating pancreatic cancer Jan, 2034

(11 years from now)

US9511046

(Pediatric)

ABRAXIS BIOSCIENCE Methods of treating pancreatic cancer Jul, 2034

(11 years from now)

Drugs and Companies using PACLITAXEL ingredient

Treatment: Treatment of lung cancer; treatment of pancreatic cancer; Treatment of pancreatic cancer; treatment of lung cancer; treatment of breast cancer; Treatment of breast cancer; treatment of pancreatic cancer; treatment of lung cancer; Treatment of lung cancer; treatment of breast cancer; treatment of pancreatic cancer; Treatment of lung cancer; Treatment of pancreatic cancer

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
100MG/VIAL POWDER;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.